期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

第56届美国血液学会年会：复发／难治急性髓细胞白血病临床治疗的研究进展 被引量：1

The 56th American Society of Hematology annual meeting： advances in clinical trials on relapse/refractory acute myeloid leukemia
原文传递
导出
摘要 急性髓系白血病（AML）为1类遗传学高度异质性的血液系统恶性疾病，无论是疾病复发／难治（R／R），治疗效果往往较差。目前仍缺乏有效的治疗策略，随着对AML发病机制的深入研究，新型化疗药物及化疗组合方案层出不穷。2014年第56届美国血液学会（AsH）年会报道的关于R／RAML的临床研究，无疑为攻克此类疾病带来新希望。笔者拟就R／RAML临床治疗的研究进展进行综述。 Acute myeloid leukemia （AML） is a kind of heterogeneous disease. Whether the disease is relapse/refractory （R/R） or not, therapeutic effects are often poor. Now, it is still lack of effective therapy to solve this problem. With the in-depth study of the pathogenesis of AML, new chemotherapy drugs and chemotherapy combination emerge in an unending flow. The 56th American Society of Hematology （ASH） shares results of R/R AML clinical studies, which opening up new prospects for R/R AML treatment.
作者 张娜 郝彩霞 王健红 梁蓉
机构地区 第四军医大学西京医院血液内科
出处 《国际输血及血液学杂志》 CAS 2015年第4期335-339,共5页 International Journal of Blood Transfusion and Hematology
基金 基金项目：国家自然科学基金资助项目（81360641）
关键词 白血病 髓样 急性 复发 临床试验 Leukemia, myeloid, acute, Recurrence Clinical trial
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献14

  • 1李群华,杜欣,黄梓伦,罗成伟,钟立业,林伟.吡柔比星联合化疗治疗成人高危或难治复发急性白血病的评价[J].中华医学杂志,2005,85(17):1195-1197. 被引量：11
  • 2黄芬,孟凡义.吡柔比星联合化疗方案治疗初治高危、复发难治性急性白血病111例疗效分析[J].中华血液学杂志,2006,27(7):481-482. 被引量：5
  • 3Ravandi F. Primary refractory acute myeloid leukaemia- in search of better definitions and therapies [J]. Br J Haematol, 2011,155(4):413-419.
  • 4King ME Rowe JM. Recent developments in acute myeloge- nous leukemia therapy[J]. Oncologist, 2007, 12 Suppl 2:14-21.
  • 5Ferrara E Palmieri S, Mele G. Prognostic factors and therapeu- tic options for relapsed or refractory acute myeloid leukemia[ J ]. Haematologica, 2004, 89(8 ):998-1008.
  • 6Kudo K, Kojima S, Tabuchi K, et al. Prospective study of a pirarubicin, intermediate- dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol, 2007, 25(34):5442-5447.
  • 7Greenberg PL, Lee S J, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase Ⅲ trial (E2995) [J]. J Clin Oncol, 2004, 22(6):1078-1086.
  • 8Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [J]. Blood, 2009, 114(5):937-951.
  • 9张之南,沈悌.血液病诊断及疗效标棒[M].3版.北京:科学出版社,2007:131-134.
  • 10Schimmer AD, Estey EH, Borthakur G, et al. Phase Ⅰ/Ⅱ trial of AEG35156 X- linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia[J]. J Clin Oncol, 2009, 27(28):4741-4746.

共引文献6

同被引文献35

  • 1Roboz GJ. Current treatment of acute myeloid leukemia[J]. Curr Opin Oncol, 2012, 24 (6): 711-719. DOI: 10. 1097/CCO. 0b013e328358f62d.
  • 2Ramos NR,Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia[J]. JClinMed,2015,4(4):665-695. DOI: 10.3390/jcm4040665.
  • 3Dias BG,Maddox SA, Klengel T, et al. Epigenetic mechanisms underlying learning and the inheritance of learned behaviors[J]. Trends Neurosci,2015,38(2):96-107. DOI: 10. 1016/j. tins. 2014.12. 003.
  • 4Hattori N, Ushijima T. Compendium of aberrant DNA methylation and histone modifications in cancer [J]. Biochem Biophys Res Commun, 2014, 455(1-2): 3-9. DOI: 10. 1016/j. bbrc. 2014.08. 140.
  • 5Yohe S. Molecular genetic markers in acute myeloid leukemia [J]. J Clin Med, 2015, 4 (3): 460-478. DOI: 10. 3390/ jcm4030460.
  • 6Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AMI.[J]. Blood, 2009,113(6) : 1315-1325. DOI: 10. 1182/blood-2008-06-163246.
  • 7Akalin A,Carrett-Bakelman FE, Kormaksson M, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscape in acute myeloid leukemias[J]. PLoS Genet,2012,8(6) :e1002781 DOI:10. 1371/journal. pgen. 1002781.
  • 8Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation E J3. Nat Genet, 2011,44 (1) :23-31. DOI: 10. 1038/ng. 1009.
  • 9Yuan XQ,Peng L, Zeng WJ, et al predict a poor prognosis in AML: patients[J]. Medicine (Baltimore), 10. 1097/MD. 0000000000003519.
  • 10Meyer SE, Qin T, Muench DNMT3A R882 mutations a meta-analysis from 4 474 2016,95(18): e3519. DOI: DE, et al. DNMT3Ahaploinsufficiency transforms FLT31TD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia [J]. Cancer Discov, 2016, 6 (5) : 501-515. DOI: 10. 1158/2159-8290. CD-16-0008.

引证文献1

二级引证文献5

国际输血及血液学杂志
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部